A Phase 3, Multicenter, Open-Label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005, Incorporating Amendment 1.

Trial Profile

A Phase 3, Multicenter, Open-Label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005, Incorporating Amendment 1.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2011

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 20 Aug 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 20 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 May 2009 Additional trial locations (Mexico, Peru, Romania, Ukraine) added as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top